Published in Genetics and Environmental Business Week, December 2nd, 2004
These results reflect the implementation of the company's previously announced decision to focus on diagnostic and therapeutic discovery and related intellectual property-based commercialization and alliances. As part of this ongoing implementation, the company has discontinued the marketing of certain software tools and other products.
"During the past quarter, we signed our first diagnostic pipeline agreement with Diagnostic Products Corp. (DP), and published our findings with respect to RNA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week